CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2017.04.014

Abstract

Abstract: The current incidence of malignant tumors is increasing.Although we have been exploring the mechanism of tumor development and its treatment,its efficacy is little.Malignant tumor development mechanism is very complex,and a variety of proteins and genes involved.Connective tissue growth factor(CTGF,also known as CCN2)is a secreted protein,a member of the CCN family,which plays a very important role in the development and progression of tumors.This article summarizes the structure and function of CTGF /CCN2 protein,the mechanism of action in the development of malignant tumors and the latest research progress in targeted therapy.

Key words: CTGF/CCN2 protein, Structural function, Malignancy, Targeted therapy

CLC Number:

SUN Yuqi,CHEN Xiuwei. Research progress of CTGF/CCN2 in the development and targeted therapy of malignant tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 363-366.

References

1 Kubota S,Takigawa M.Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological condition[J].Clin Sci,2015,128(3):181-196.
2 Perbal B.CCN proteins:A centralized communication network[J].J Cell Commun Signal,2013,7(3):169-177.
3 Yang K,Gao K,Hu G,et al.CTGF enhances resistance to 5-Fu-mediating cell aprotosis through FAK/MEK/ERK signal pathway in colorectal cancer[J].Onco Targets Ther,2016,9:7285-7295.
4 Xue X,Fan X,Qu Q,et al.Bioscreening and expression of a camel anti-CTGF VHH nanobody and its renaturation by a novel dialysis-dilation method[J].AMB Express,2016,6(1):72.
5 Jiang J,Leong NL,Khalique U,et al.Connective tissue growth factor(CTGF/CCN2)in haemophilic arthropathy and arthrofibrosis:a histological analysis[J].Haemophilia,2016,22(6):527-536.
6 Greeiten KG,Bovenschem N,Nguyen TQ,et al.Rapid hepatic clearance of full length CCN2/CTGF:a putative role for LRP1-mediated endocytosis[J].J Cell Commun Signal,2016,10(4):295-303.
7 Mendes FA,Coelho Aquiar JM,Kahn SA,et al.Connective-tissue growth factor(CTGF/CCN2)induces astrogenesis and fibronectin expression of embryonic neural cells in vitro[J].PLoS One,2015,10(8):e0133689.
8 Riser BL,Barnes JL,Varani J,et al.Balanced regulation of the CCN family of matricellular proteins:a novel approach to the prevention and treatment of fibrosis and cancer[J].J Cell Singal,2015,9(4):327-339.
9 Purohit T,Qin Z,Quan C,et al.Smad-3 dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts[J].PLoS One,2017,12(3):e0173191.
10 Ding ZY,Jin GN,Wang W,et al.Activin a-smad singaling mediates connective tissue growth factor synthesis in liver progenitor cells[J].Int J Mol Sci,2016,17(3):408.
11 Toda N,Mori K,Kasahara M,et al.Curcial role of mesangial cell-derived connective tissue growth factor in a mouse model of anti-glomerular basement membrance glomerulonephritis[J].Sci Rep,2017,7:42114.
12 Chatzigrangkeskou M,Le Dour C,Wu W,et al.ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene[J].Hum Mol Genet,2016,25(11):2220-2233.
13 Leask A.CCN2 in skin fibrosis[J].Methods Mol Biol,2017,1489:417-421.
14 Accornero F,Correll RN,van Berlo JH,et al.Genetic anlysis of connective tissue growth factor as an effector of transforming growth factor β signaling and cardiac remodeling[J].Mol Cell Biol,2015,35(12):2154-2164.
15 Yang Z,Sun Z,Liu H,et al.Connective tissue growth factor stimulates the proliferation,migration and differentiation of lung fibroblasts during paraquat-induced pulmonary fibrosis[J].Mol Med Rep,2015,12(1):1091-1097.
16 Wells JE,Howlett M,Cole CH,et al.Deregulated expression of connective tissue growth factor(CTGF/CCN2)is linked to poor outcome in human cancer[J].Int J Cancer,2015,137(3):504-511.
17 Yeger H,Perbal B.CCN family of proteins:critical modulators of the tumor cell microenvironment[J].J Cell Commun Signal,2016,10(3):229-240.
18 Ubikn I,Verhaar ER,Kranenburg O,et al.A potential role for CCN2/CTGF in aggressive colorectal cancer[J].J Cell Commun Signal,2016,10(3):223-227.
19 Kato S,Yokoyama S,Hayakawa Y,et al.P38 pathway as a key downstream signal of connective tissue growth factor to regulate metastatic potential in non-small-cell lung cancer[J].Cancer Sci,2016,107(10):1416-1421.
20 Guo Y,Li X,Lin C,et al.MicroRNA133b inhibits connective tissue growth factor in colorectal cancer and correlates with the clinical stage of the disease[J].Mol Med Rep,2015,11(4):2805-2812.
21 Lacle MM,van Diest PJ,Goldschmeding R,et al.Expression of connective tissue growth factor in male breast cancer:clinicopathologic correlations and prognostic value[J].PLoS One,2015,10(3):e0118957.
22 Sun D,Han S,Lin C,et al.Microrna-199a-5p functions as a tumor suppressor via suppressing connective tissue growth factor(CTGF)in follicular thyroid carcinoma[J].Med Sci Mont,2016,22:1210-1217.
23 Sandra RM,Raquel RD,Jose Luis MP,et al.Connective tissue growh factor is a new ligand of epiderma growth factor receptor[J].J Mol Cell Biol,2013,5(5):323-335.
24 Chen CN,Chang CC,Lai HS,et al.Connectiv tissue growth factor inhibits gastric cancer peritoneal metastasis by blocking intergrin α3β1-dependent adhesion[J].Gastric Cancer,2015,18(3):504-515.
25 Li J,Ye L,Owen S,et al.Emeriging role of CCN family proteins in tumorigenesis and cancer metastasis[J].Int J Mol Med,2015,36(6):1451-1463.
26 Jung HY,Fattet L,Yang J,et al.Molecular pathway:linking tumor microenvironment to epthelial-mesenchymal transition in metastasis[J].Clin Cancer Res,2015,21(5):962-968.
27 Hutchenereuther J,Vincent KM,Carter DE,et al.CCN2 expression by tumor stroma is required for melanoma metastasis[J].J Invest Dermatol,2015,135(11):2805-2813.
28 Wang Q,Xu Z,An Q,et al.TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells[J].Mol Med Rep,2015,11(2):982-988.
29 Han Q,Zhang HY,Zhong BL,et al.MicroRNA-145 inhibits cell migration and invasion and regulates epithelial-mesenchymal transition(EMT)by targeting connective tissue growth factor(CTGF)in esophageal squamous cell carcinoma[J].Med Sci Monit,2016,22:3925-3934.
30 Li J,Gao X,Ji K,et al.Differential expression of CCN family members CYR61,CTGF and NOV in gastric cancer and their association with disease progression[J].Oncol Rep,2016,36(5):2517-2525.
31 Kim MJ,Gloss BS,Murali R,et al.Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer[J].Oncotarget,2015,6(42):445551-44562.
32 Huang Y,Zhao S,Zhang C,et al.Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells[J].Mol Med Rep,2016,13(2):1888-1894.
33 Tian T,Li A,Lu H,et al.Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective growth factor[J].Am J Cancer Res,2015,5(5):1823-1830.
34 Chang CC,Hsu WH,Wang CC,et al.Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells[J].Cancer Res,2013,73(13):4147-4157.
35 Shimo T,Takigawa M.Cell biological assays for measuring angiogenic activities of CCN proteins[J].Methods Mol Biol,2017,1489:239-249.
36 Pi L,Shenoy AK,Liu J,et al.CCN2/CTGF regulates neovessel formation via targeting structurally conserved cystine knotmotifs in multiple angiogenic regulators[J].FASEB,2012,26(8):3365-3379.
37 Wang LH,Tsai HC,Cheng YC,et al.CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling[J].Cancer Lett,2017,391:28-37.
38 Kleer CG.Dual roles of CCN proteins in breast cancer progression[J].J Cell Commun Signal,2016,10(3):217-222.
39 Tsai HC,Huang CY,Su HL,et al.CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells[J].Biochim Biophys Acta,2014,1843(5):846-854.
40 Jia Q,Dong Q,Qin L,et al.CCN:Core regulatory proteins in the microenvironment that affect the metastasis of hepatocellular carcinoma?[J].Oncotarget,2016,7(2):1203-1214.
41 Tsai HC,Huang CY,Su HL,et al.CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma[J].PLoS One,2014,9(3):e90159.

[1]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[2]	HAN Teng, TANG Liping. Advances in the relationship between the PD-L1 expression and the prognosis of gynecologic malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 468-470.
[3]	HUANG Qianqian, MA Jianjia, WU Qiang, LIU Binbin, MU Xiaoqin, LIU Shulin. Research progress on tumor stem cells and tumor targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 533-537.
[4]	ZUO Zhichao, SU Danke, DENG Wenjuan, JIN Guanqiao. Recent advances of ELAM-1 in targeted cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 444-447.
[5]	SANG Xiuli, SHI Ce, ZHOU Jin. The research development of Chimeric Antigen Receptor T-cells in hematological malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 473-476.
[6]	LV Fulian, GAO Xiang, JIN Aishun. Functional characteristic research progress of DCLK1 as a potential biomarker in cancer stem cells for gastrointestinal onalignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 458-461.
[7]	LIU Enrui,REN Huan,ZHAO Yu,SU Jun. Advanced research on characteristics of the classical subtype of human glioblastoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 136-139.
[8]	YAN Xiaofei,HAN Bo. The treatment and prospects of locally advanced nasopharyngeal carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 149-152.
[9]	LI Sen,LI Zhiguo,CHENG Long,XUE Yingwei. Progress of targeted therapy in Her-2 positive gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 188-192.
[10]	QIU Zidan,LI Jiancheng. Molecular targeted therapy for esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 57-60.
[11]	LUO Jianing,GE Xiaofeng. Drug treatment status and research progress on triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 89-92.
[12]	ZHANG Meng,ZHANG Jiewu,KONG Lingyu. The inhibition of skin tumor growth in Galectin-3-deficient mice [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 305-309.
[13]	MA RuiJin,YANG Yu. The research development of PI3K/AKT/mTOR signaling pathway in HER2 resistance for the treatment of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 360-363.
[14]	SONG chunyu,QU guofan. New progress in the study of gene- targeted threapy for osteosacoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 364-366.
[15]	REN Fenghai,XU Shidong. New development of PLK1 targeted therapy in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2013, 27(5): 436-439.

Research progress of CTGF/CCN2 in the development and targeted therapy of malignant tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments